Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)‘s stock had its “buy” rating reaffirmed by Maxim Group in a note issued to investors on Wednesday. They presently have a $52.00 target price on the stock, down from their prior target price of $72.00. Maxim Group’s price objective would suggest a potential upside of 33.71% from the stock’s previous close.

TEVA has been the topic of a number of other research reports. RBC Capital Markets set a $71.00 price target on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a research report on Sunday, September 11th. Mizuho reiterated a “buy” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, July 25th. Bank of America Corp. set a $72.00 target price on Teva Pharmaceutical Industries and gave the company a “buy” rating in a report on Saturday, October 1st. Leerink Swann reissued an “outperform” rating and set a $66.00 target price on shares of Teva Pharmaceutical Industries in a report on Tuesday, August 16th. Finally, Piper Jaffray Cos. reissued a “neutral” rating and set a $57.00 target price (up previously from $55.00) on shares of Teva Pharmaceutical Industries in a report on Monday, August 8th. Thirteen equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $60.00.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at 38.89 on Wednesday. The company has a market capitalization of $35.55 billion, a price-to-earnings ratio of 25.98 and a beta of 0.73. The stock has a 50 day moving average price of $42.97 and a 200 day moving average price of $49.87. Teva Pharmaceutical Industries has a 1-year low of $37.25 and a 1-year high of $66.55.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Tuesday, November 15th. The company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.29 by $0.02. The company had revenue of $5.56 billion for the quarter, compared to the consensus estimate of $5.71 billion. Teva Pharmaceutical Industries had a return on equity of 17.77% and a net margin of 7.56%. Teva Pharmaceutical Industries’s revenue for the quarter was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.35 earnings per share. On average, equities analysts anticipate that Teva Pharmaceutical Industries will post $5.16 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 20th. Shareholders of record on Monday, December 5th will be issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.50%. Teva Pharmaceutical Industries’s dividend payout ratio (DPR) is 58.39%.

Hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its stake in shares of Teva Pharmaceutical Industries by 2.6% in the third quarter. Price T Rowe Associates Inc. MD now owns 6,293,135 shares of the company’s stock worth $289,547,000 after buying an additional 157,944 shares during the period. Crow Point Partners LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth about $169,000. Schafer Cullen Capital Management Inc. increased its stake in shares of Teva Pharmaceutical Industries by 43.5% in the third quarter. Schafer Cullen Capital Management Inc. now owns 10,565 shares of the company’s stock worth $486,000 after buying an additional 3,205 shares during the period. Salem Investment Counselors Inc. increased its stake in shares of Teva Pharmaceutical Industries by 9.5% in the third quarter. Salem Investment Counselors Inc. now owns 6,625 shares of the company’s stock worth $305,000 after buying an additional 575 shares during the period. Finally, Verition Fund Management LLC increased its stake in shares of Teva Pharmaceutical Industries by 25.3% in the third quarter. Verition Fund Management LLC now owns 36,910 shares of the company’s stock worth $1,698,000 after buying an additional 7,445 shares during the period. 63.00% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.